The Effect of Systemic Chemotherapy on Neurogenesis, Plasticity and Memory

Chapter
First Online:
Part of the Current Topics in Behavioral Neurosciences book series (CTBN, volume 15)

Abstract

Chemotherapy has been enormously successful in treating many forms of cancer and improving patient survival rates. With the increasing numbers of survivors, a number of cognitive side effects have become apparent. These have been called “chemobrain” or “chemofog” among patient groups, who describe the symptoms as a decline in memory, concentration and executive functions. Changes which, although subtle, can cause significant distress among patients and prevent a return to the quality of life experienced before treatment. This cognitive side effect of chemotherapy was not anticipated as it had been assumed that chemotherapy agents, administered systematically, could not cross the blood–brain barrier and that the brain was therefore protected from their action. It is now realised that low concentrations of many chemotherapy agents cross the blood–brain barrier and even those that are completely prevented from doing so, can induce the production of inflammatory cytokines in peripheral tissues which in turn can cross the blood–brain barrier and impact on the brain. A large number of patient studies have shown that cognitive decline is found in a proportion of patients treated with a variety of chemotherapy agents for different types of cancer. The deficits experienced by these patients can last for up to several years and have a deleterious effect on educational attainment and ability to return to work. Imaging studies of patients after systemic chemotherapy show that this treatment produces structural and functional changes in the brain some of which seem to persist even when the cognitive deficits have ceased. This suggests that, with time, brain plasticity may be able to compensate for the deleterious effects of chemotherapy treatment. A number of mechanisms have been suggested for the changes in brain structure and function found after chemotherapy. These include both central and peripheral inflammatory changes, demyelination of white matter tracts, a reduction in stem cell proliferation in both the hippocampal neurogenic region and by oligodendrocyte precursors as well as changes in hormonal or growth factor levels. A number of possible treatments have been suggested which range from pharmacological interventions to cognitive behavioural therapies. Some of these have only been tested in animal models while others have produced varying degrees of improvement in patient populations. Currently, there is no recognised treatment and a greater understanding of the causes of the cognitive decline experienced after chemotherapy will be key to finding ways of preventing or treating the effects of chemobrain.

Keywords

Cognitive Decline Neural Stem Cell Systemic Chemotherapy Chemotherapy Agent White Matter Tract 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Abraham J, Haut MW, Moran MT, Filburn S, Lemiuex S, Kuwabara H (2008) Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 8:88–91PubMedGoogle Scholar
  2. Adamcio B, Sargin D, Stradomska A, Medrihan L, Gertler C, Theis F, Zhang M, Muller M, Hassouna I, Hannke K et al (2008) Erythropoietin enhances hippocampal long-term potentiation and memory. BMC Biol 6:37PubMedGoogle Scholar
  3. Agrawal K, Onami S, Mortimer JE, Pal SK (2010) Cognitive changes associated with endocrine therapy for breast cancer. Maturitas 67:209–214PubMedGoogle Scholar
  4. Ahles TA (2012) Brain vulnerability to chemotherapy toxicities. Psychooncology 21:1141–1148Google Scholar
  5. Ahles TA, Saykin AJ (2007) Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 7:192–201PubMedGoogle Scholar
  6. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, Whedon MB, Bivens S, Mitchell T, Greenberg ER et al (2002) Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485–493PubMedGoogle Scholar
  7. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Titus-Ernstoff L, Skalla K, Bakitas M, Silberfarb PM (2005) Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy. J Clin Oncol 23:4399–4405PubMedGoogle Scholar
  8. Ahles TA, Saykin AJ, McDonald BC, Li Y, Furstenberg CT, Hanscom BS, Mulrooney TJ, Schwartz GN, Kaufman PA (2010) Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol 28:4434–4440PubMedGoogle Scholar
  9. Ahles TA, Saykin AJ, Noll WW, Furstenberg CT, Guerin S, Cole B, Mott LA (2003) The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612–619PubMedGoogle Scholar
  10. Akatsu Y, Saikawa Y, Kubota T, Akatsu T, Yoshida M, Kitagawa Y, Otani Y, Kumai K, Kitajima M (2007) Predictive value of GADD153, p21 and c-Jun for chemotherapy response in gastric cancer. Cancer Sci 98:707–715PubMedGoogle Scholar
  11. Akitake R, Miyamoto S, Nakamura F, Horimatsu T, Ezoe Y, Muto M, Chiba T (2011) Early detection of 5-FU-induced acute leukoencephalopathy on diffusion-weighted MRI. Jpn J Clin Oncol 41:121–124PubMedGoogle Scholar
  12. Aluise CD, Sultana R, Tangpong J, Vore M, St Clair D, Moscow JA, Butterfield DA (2010). Chemo brain (chemo fog) as a potential side effect of doxorubicin administration: role of cytokine-induced, oxidative/nitrosative stress in cognitive dysfunction. Adv Exp Med Biol 678:147–156Google Scholar
  13. Baj G, D’Alessandro V, Musazzi L, Mallei A, Sartori CR, Sciancalepore M, Tardito D, Langone F, Popoli M, Tongiorgi E (2012) Physical exercise and antidepressants enhance BDNF targeting in hippocampal CA3 dendrites: further evidence of a spatial code for BDNF splice variants. Neuropsychopharmacology 37:1600–1611PubMedGoogle Scholar
  14. Bastos GN, Moriya T, Inui F, Katura T, Nakahata N (2008) Involvement of cyclooxygenase-2 in lipopolysaccharide-induced impairment of the newborn cell survival in the adult mouse dentate gyrus. Neuroscience 155:454–462PubMedGoogle Scholar
  15. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, Wu Z, Holtzman DM, Betsholtz C, Armulik A, Sallstrom J et al (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485:512–516PubMedGoogle Scholar
  16. Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, Ryan CM (2006) Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422–430PubMedGoogle Scholar
  17. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P, Cohen SM, Casillo FE, Berga SL (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause 14:995–998PubMedGoogle Scholar
  18. Bidwell LC, McClernon FJ, Kollins SH (2011) Cognitive enhancers for the treatment of ADHD. Pharmacol Biochem Behav 99:262–274PubMedGoogle Scholar
  19. Biegler KA, Chaoul MA, Cohen L (2009) Cancer, cognitive impairment, and meditation. Acta Oncol 48:18–26PubMedGoogle Scholar
  20. Biglia N, Bounous VE, Malabaila A, Palmisano D, Torta DM, D’Alonzo M, Sismondi P, Torta R (2012) Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl) 21:485–492Google Scholar
  21. Blaney SM, Berg SL, Boddy AV (2004) Drug delivery. In: Walker DA, Perilongo G, Punt G, Taylor RE (eds) Brain and spinal tumours of childhood. Hodder Arnold, LondonGoogle Scholar
  22. Boldrini M, Underwood MD, Hen R, Rosoklija, GB, Dwork AJ, John Mann J, Arango V (2009). Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 34:2376–2389Google Scholar
  23. Bourke RS, West CR, Chheda G, Tower DB (1973) Kinetics of entry and distribution of 5-fluorouracil in cerebrospinal fluid and brain following intravenous injection in a primate. Cancer Res 33:1735–1746PubMedGoogle Scholar
  24. Boykoff N, Moieni M, Subramanian SK (2009) Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response. J Cancer Surviv 3:223–232PubMedGoogle Scholar
  25. Brann DW, Dhandapani K, Wakade C, Mahesh VB, Khan MM (2007) Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids 72:381–405PubMedGoogle Scholar
  26. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF (2000) Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695–2701PubMedGoogle Scholar
  27. Briones TL, Woods J (2011) Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications. BMC Neurosci 12:124PubMedGoogle Scholar
  28. Bruno J, Hosseini SM, Kesler S (2012) Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis 48:329–338PubMedGoogle Scholar
  29. Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8:729–740PubMedGoogle Scholar
  30. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA (2004) Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955–969PubMedGoogle Scholar
  31. Castren E, Rantamaki T (2010) The role of BDNF and its receptors in depression and antidepressant drug action: reactivation of developmental plasticity. Dev Neurobiol 70:289–297PubMedGoogle Scholar
  32. Chang J, Couture FA, Young SD, Lau CY, Lee McWatters K (2004). Weekly administration of epoetin alfa improves cognition and quality of life in patients with breast cancer receiving chemotherapy. Support Cancer Ther 2:52–58Google Scholar
  33. Cho YK, Kim G, Park S, Sim JH, Won YJ, Hwang CH, Yoo JY, Hong HN (2012) Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice culture. Biochem Biophys Res Commun 417:753–759PubMedGoogle Scholar
  34. Christie LA, Acharya MM, Parihar VK, Nguyen A, Martirosian, V, Limoli CL (2012) Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy. Clin Cancer Res 18:1954–1965Google Scholar
  35. Cimprich B, Reuter-Lorenz P, Nelson J, Clark PM, Therrien B, Normolle D, Berman MG, Hayes DF, Noll DC, Peltier S et al (2010) Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 32:324–331PubMedGoogle Scholar
  36. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S (2009) Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18:134–143PubMedGoogle Scholar
  37. Correa DD, Hess LM (2012) Cognitive function and quality of life in ovarian cancer. Gynecol Oncol 124:404–409PubMedGoogle Scholar
  38. Cotman CW, Berchtold NC, Christie LA (2007) Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends Neurosci 30:464–472PubMedGoogle Scholar
  39. Cueva JF, Calvo M, Anido U, Leon L, Gallardo E, Areses C, Bernardez B, Gayoso L, Garcia J, Jesus Lamas M et al (2012). Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study. Invest New Drugs 30:688–694Google Scholar
  40. Dabrowska M, Mosieniak G, Skierski J, Sikora E, Rode W (2009) Methotrexate-induced senescence in human adenocarcinoma cells is accompanied by induction of p21(waf1/cip1) expression and lack of polyploidy. Cancer Lett 284:95–101PubMedGoogle Scholar
  41. Dabrowska M, Skoneczny M, Rode W (2011) Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol 32:965–976PubMedGoogle Scholar
  42. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FS et al (2011a) Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 33:2971–2983Google Scholar
  43. de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, Boven E, Schagen SB (2011b) Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32:1206–1219PubMedGoogle Scholar
  44. De Waele S, Van Belle S (2010) Cancer-related fatigue. Acta Clin Belg 65:378–385PubMedGoogle Scholar
  45. Debess J, Riis JO, Engebjerg MC, Ewertz M (2010) Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat 121:91–100PubMedGoogle Scholar
  46. Deng W, Aimone JB, Gage FH (2010) New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory? Nat Rev Neurosci 11:339–350PubMedGoogle Scholar
  47. Deprez S, Amant F, Smeets A, Peeters R, Leemans A, Van Hecke W, Verhoeven JS, Christiaens MR, Vandenberghe J, Vandenbulcke M et al (2012) Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 30:274–281PubMedGoogle Scholar
  48. Deprez S, Amant F, Yigit R, Porke K, Verhoeven J, Van den Stock J, Smeets A, Christiaens MR, Leemans A, Van Hecke W et al (2011) Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 32:480–493PubMedGoogle Scholar
  49. Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M (2006) CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 5:22PubMedGoogle Scholar
  50. Donovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB (2005) Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104:2499–2507PubMedGoogle Scholar
  51. Ekdahl CT, Kokaia Z, Lindvall O (2009) Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 158:1021–1029PubMedGoogle Scholar
  52. ElBeltagy M, Mustafa S, Umka J, Lyons L, Salman A, Chur-yoe GT, Bhalla N, Bennett G, Wigmore PM (2010) Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil. Behav Brain Res 208:112–117PubMedGoogle Scholar
  53. ElBeltagy M, Mustafa S, Umka J, Lyons L, Salman A, Dormon K, Allcock C, Bennett G, Wigmore P (2012) The effect of 5-fluorouracil on the long term survival and proliferation of cells in the rat hippocampus. Brain Res Bull 88:514–518PubMedGoogle Scholar
  54. Elsea CR, Roberts DA, Druker BJ, Wood LJ (2008) Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity. PLoS One 3:e2355PubMedGoogle Scholar
  55. Encinas JM, Vaahtokari A, Enikolopov G (2006) Fluoxetine targets early progenitor cells in the adult brain. Proc Natl Acad Sci USA 103:8233–8238PubMedGoogle Scholar
  56. Fan HG, Park A, Xu W, Yi QL, Braganza S, Chang J, Couture F, Tannock IF (2009) The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer. Psychooncology 18:156–161PubMedGoogle Scholar
  57. Fardell JE, Vardy J, Johnston IN, Winocur G (2011) Chemotherapy and cognitive impairment: treatment options. Clin Pharmacol Ther 90:366–376PubMedGoogle Scholar
  58. Fardell JE, Vardy J, Logge W, Johnston I (2010) Single high dose treatment with methotrexate causes long-lasting cognitive dysfunction in laboratory rodents. Pharmacol Biochem Behav 97:333–339PubMedGoogle Scholar
  59. Fardell JE, Vardy J, Shah JD, Johnston IN (2012) Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity. Psychopharmacology (Berl) 220:183–193Google Scholar
  60. Ferguson RJ, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA, Saykin AJ (2012) Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology 21:176–186PubMedGoogle Scholar
  61. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA (2007) Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 25:3866–3870PubMedGoogle Scholar
  62. Fremouw T, Fessler CL, Ferguson RJ, Burguete Y (2012a) Preserved learning and memory in mice following chemotherapy: 5-Fluorouracil and doxorubicin single agent treatment, doxorubicin-cyclophosphamide combination treatment. Behav Brain Res 226:154–162PubMedGoogle Scholar
  63. Fremouw T, Fessler CL, Ferguson RJ, Burguete Y (2012b) Recent and remote spatial memory in mice treated with cytosine arabinoside. Pharmacol Biochem Behav 100:451–457PubMedGoogle Scholar
  64. Gagnon B, Low G, Schreier G (2005) Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci 30:100–107PubMedGoogle Scholar
  65. Galalae RM, Michel J, Siebmann JU, Kuchler T, Eilf K, Kimmig B (2005) Significant negative impact of adjuvant chemotherapy on health-related quality of life (HR-QoL) in women with breast cancer treated by conserving surgery and postoperative 3-D radiotherapy. A prospective measurement. Strahlenther Onkol 181:645–651PubMedGoogle Scholar
  66. Galica J, Rajacich D, Kane D, Pond GR (2012) The impact of chemotherapy-induced cognitive impairment on the psychosocial adjustment of patients with nonmetastatic colorectal cancer. Clin J Oncol Nurs 16:163–169PubMedGoogle Scholar
  67. Gallassi R, Di Sarro R, Morreale A, Amore M (2006) Memory impairment in patients with late-onset major depression: the effect of antidepressant therapy. J Affect Disord 91:243–250PubMedGoogle Scholar
  68. Gandal MJ, Ehrlichman RS, Rudnick ND, Siegel SJ (2008) A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience 157:95–104PubMedGoogle Scholar
  69. Garthe A, Behr J, Kempermann G (2009) Adult-generated hippocampal neurons allow the flexible use of spatially precise learning strategies. PLoS One 4:e5464PubMedGoogle Scholar
  70. Gewirtz DA, Holt SE, Elmore LW (2008) Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 76:947–957PubMedGoogle Scholar
  71. Goldman SA, Chen Z (2011) Perivascular instruction of cell genesis and fate in the adult brain. Nat Neurosci 14:1382–1389PubMedGoogle Scholar
  72. Gottschalk LA, Holcombe RF, Jackson D, Bechtel RJ (2003) The effects of anticancer chemotherapeutic drugs on cognitive function and other neuropsychiatric dimensions in breast cancer patients. Methods Find Exp Clin Pharmacol 25:117–122PubMedGoogle Scholar
  73. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M (2008) Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 7:12PubMedGoogle Scholar
  74. Hardwicke S (2009) Chemo brain and recovery. A guide for survival. eBook Vabion LLCGoogle Scholar
  75. Hedayati E, Alinaghizadeh H, Schedin A, Nyman H, Albertsson M (2012) Effects of adjuvant treatment on cognitive function in women with early breast cancer. Eur J Oncol Nurs 16:315–322PubMedGoogle Scholar
  76. Hein AM, O’Banion MK (2009) Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol 40:15–32PubMedGoogle Scholar
  77. Hermelink K, Henschel V, Untch M, Bauerfeind I, Lux MP, Munzel K (2008) Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: results of a multicenter, prospective, longitudinal study. Cancer 113:2431–2439PubMedGoogle Scholar
  78. Hermelink K, Kuchenhoff H, Untch M, Bauerfeind I, Lux MP, Buhner M, Manitz J, Fensterer V, Munzel K (2010) Two different sides of ‘chemobrain’: determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 19:1321–1328PubMedGoogle Scholar
  79. Hermelink K, Untch M, Lux MP, Kreienberg R, Beck T, Bauerfeind I, Munzel K (2007) Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 109:1905–1913PubMedGoogle Scholar
  80. Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML, Warsi SP, Waller JL, Terry AV Jr (2006) Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther 316:679–694Google Scholar
  81. Herrmann N, Chau SA, Kircanski I, Lanctot KL (2011) Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs 71:2031–2065PubMedGoogle Scholar
  82. Hess LM, Chambers SK, Hatch K, Hallum A, Janicek MF, Buscema J, Borst M, Johnson C, Slayton L, Chongpison Y et al (2010) Pilot study of the prospective identification of changes in cognitive function during chemotherapy treatment for advanced ovarian cancer. J Support Oncol 8:252–258PubMedGoogle Scholar
  83. Hobl EL, Mader RM, Erlacher L, Duhm B, Mustak M, Broll H, Hogger P, Kalipciyan M, Jilma B (2011) The influence of methotrexate on the gene expression of the pro-inflammatory cytokine IL-12A in the therapy of rheumatoid arthritis. Clin Exp Rheumatol 29:963–969PubMedGoogle Scholar
  84. Horsfield SA, Rosse RB, Tomasino V, Schwartz BL, Mastropaolo J, Deutsch SI (2002) Fluoxetine’s effects on cognitive performance in patients with traumatic brain injury. Int J Psychiatry Med 32:337–344PubMedGoogle Scholar
  85. Huang GJ, Ben-David E, Tort Piella A, Edwards A, Flint J, Shifman S (2012) Neurogenomic evidence for a shared mechanism of the antidepressant effects of exercise and chronic fluoxetine in mice. PLoS One 7:e35901Google Scholar
  86. Huang L, Wong YP, Cai YJ, Lung I, Leung CS, Burd A (2010) Low-dose 5-fluorouracil induces cell cycle G2 arrest and apoptosis in keloid fibroblasts. Br J Dermatol 163:1181–1185PubMedGoogle Scholar
  87. Huang WY, Yang PM, Chang YF, Marquez VE, Chen CC (2011) Methotrexate induces apoptosis through p53/p21-dependent pathway and increases E-cadherin expression through downregulation of HDAC/EZH2. Biochem Pharmacol 81:510–517PubMedGoogle Scholar
  88. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D’Andrea G et al (2006) Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 54:925–931PubMedGoogle Scholar
  89. Iconomou G, Koutras A, Karaivazoglou K, Kalliolias GD, Assimakopoulos K, Argyriou AA, Ifanti A, Kalofonos HP (2008) Effect of epoetin alpha therapy on cognitive function in anaemic patients with solid tumours undergoing chemotherapy. Eur J Cancer Care (Engl) 17:535–541Google Scholar
  90. Imayoshi I, Sakamoto M, Yamaguchi M, Mori K, Kageyama R (2010) Essential roles of Notch signaling in maintenance of neural stem cells in developing and adult brains. J Neurosci 30:3489–3498PubMedGoogle Scholar
  91. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Nakano T, Akechi T, Wada N, Imoto S, Murakami K, Uchitomi Y (2007) Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109:146–156PubMedGoogle Scholar
  92. Inokuchi K (2011) Adult neurogenesis and modulation of neural circuit function. Curr Opin Neurobiol 21:360–364PubMedGoogle Scholar
  93. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR (2011) An update on cancer- and chemotherapy-related cognitive dysfunction: current status. Semin Oncol 38:431–438PubMedGoogle Scholar
  94. Janelsins MC, Mustian KM, Palesh OG, Mohile SG, Peppone LJ, Sprod LK, Heckler CE, Roscoe JA, Katz AW, Williams JP et al (2012) Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer 20:831–839PubMedGoogle Scholar
  95. Jansen CE, Cooper BA, Dodd MJ, Miaskowski CA (2011) A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647–1656PubMedGoogle Scholar
  96. Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, Allan S, Bishop H, Hodson N, Mitra S, Sadler G et al (2006) A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828–834PubMedGoogle Scholar
  97. Jenkins V, Shilling V, Fallowfield L, Howell A, Hutton S (2004) Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 13:61–66PubMedGoogle Scholar
  98. Jim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB (2009) Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 115:1776–1783PubMedGoogle Scholar
  99. Jin Y, Lim CM, Kim SW, Park JY, Seo JS, Han PL, Yoon SH, Lee JK (2009) Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 1281:108–116PubMedGoogle Scholar
  100. Joly F, Rigal O, Noal S, Giffard B (2012) Cognitive dysfunction and cancer: which consequences in terms of disease management? Psychooncology 20:1251–1258Google Scholar
  101. Joshi G, Aluise CD, Cole MP, Sultana R, Pierce WM, Vore M, St Clair DK, Butterfield DA (2010) Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience 166:796–807Google Scholar
  102. Kendall I, Slotten HA, Codony X, Burgueno J, Pauwels PJ, Vela JM, Fone KC (2011) E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 213:413–430Google Scholar
  103. Kerr IG, Zimm S, Collins JM, O’Neill D, Poplack DG (1984) Effect of intravenous dose and schedule on cerebrospinal fluid pharmacokinetics of 5-fluorouracil in the monkey. Cancer Res 44:4929–4932PubMedGoogle Scholar
  104. Kesler SR, Bennett FC, Mahaffey ML, Spiegel D (2009) Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 15:6665–6673PubMedGoogle Scholar
  105. Kesler SR, Kent JS, O’Hara R (2011) Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 68:1447–1453PubMedGoogle Scholar
  106. Kochman LJ, Fornal CA, Jacobs BL (2009) Suppression of hippocampal cell proliferation by short-term stimulant drug administration in adult rats. Eur J Neurosci 29:2157–2165PubMedGoogle Scholar
  107. Kodama M, Fujioka T, Duman RS (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56:570–580PubMedGoogle Scholar
  108. Koehl M, Abrous DN (2011) A new chapter in the field of memory: adult hippocampal neurogenesis. Eur J Neurosci 33:1101–1114PubMedGoogle Scholar
  109. Kohli S, Fisher SG, Tra Y, Adams MJ, Mapstone ME, Wesnes KA, Roscoe JA, Morrow GR (2009) The effect of modafinil on cognitive function in breast cancer survivors. Cancer 115:2605–2616PubMedGoogle Scholar
  110. Konat GW, Kraszpulski M, James I, Zhang HT, Abraham J (2008) Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats. Metab Brain Dis 23:325–333PubMedGoogle Scholar
  111. Koppelmans V, Breteler MM, Boogerd W, Seynaeve C, Gundy C, Schagen SB (2012) Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. J Clin Oncol 30:1080–1086PubMedGoogle Scholar
  112. Koppelmans V, de Ruiter MB, van der Lijn F, Boogerd W, Seynaeve C, van der Lugt A, Vrooman H, Niessen WJ, Breteler MM, Schagen SB (2012). Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 132:1099–1106Google Scholar
  113. Kotani S, Yamauchi T, Teramoto T, Ogura H (2008) Donepezil, an acetylcholinesterase inhibitor, enhances adult hippocampal neurogenesis. Chem Biol Interact 175:227–230PubMedGoogle Scholar
  114. Kreukels BP, Hamburger HL, de Ruiter MB, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB (2008a) ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol 119:533–541PubMedGoogle Scholar
  115. Kreukels BP, van Dam FS, Ridderinkhof KR, Boogerd W, Schagen SB (2008b) Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. Clin Breast Cancer 8:80–87PubMedGoogle Scholar
  116. Kurita K, Meyerowitz BE, Hall P, Gatz M (2011) Long-term cognitive impairment in older adult twins discordant for gynecologic cancer treatment. J Gerontol A Biol Sci Med Sci 66:1343–1349PubMedGoogle Scholar
  117. Lerner C, Harrison DE (1990) 5-Fluorouracil spares hemopoietic stem cells responsible for long-term repopulation. Exp Hematol 18:114–118PubMedGoogle Scholar
  118. Li CQ, Liu D, Huang L, Wang H, Zhang JY, Luo XG (2008) Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats. Brain Res Bull 77:237–240PubMedGoogle Scholar
  119. Li Y, Vijayanathan V, Gulinello M, Cole PD (2010a) Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine. Pharmacol Biochem Behav 95:428–433PubMedGoogle Scholar
  120. Li Y, Vijayanathan V, Gulinello ME, Cole PD (2010b) Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats. Pharmacol Biochem Behav 94:454–463PubMedGoogle Scholar
  121. Lim CM, Kim SW, Park JY, Kim C, Yoon SH, Lee JK (2009) Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. J Neurosci Res 87:1037–1045PubMedGoogle Scholar
  122. Lombardero M, Kovacs K, Scheithauer BW (2011) Erythropoietin: a hormone with multiple functions. Pathobiology 78:41–53PubMedGoogle Scholar
  123. Long JM, Lee GD, Kelley-Bell B, Spangler EL, Perez EJ, Longo DL, de Cabo R, Zou S, Rapp PR (2011) Preserved learning and memory following 5-fluorouracil and cyclophosphamide treatment in rats. Pharmacol Biochem Behav 100:205–211Google Scholar
  124. Lower EE, Fleishman S, Cooper A, Zeldis J, Faleck H, Yu Z, Manning D (2009) Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38:650–662PubMedGoogle Scholar
  125. Lugert S, Basak O, Knuckles P, Haussler U, Fabel K, Gotz M, Haas CA, Kempermann G, Taylor V, Giachino C (2010) Quiescent and active hippocampal neural stem cells with distinct morphologies respond selectively to physiological and pathological stimuli and aging. Cell Stem Cell 6:445–456PubMedGoogle Scholar
  126. Lundorff LE, Jonsson BH, Sjogren P (2009) Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial. Palliat Med 23:731–738PubMedGoogle Scholar
  127. Lyons L, Bennett G, Wigmore P (2011a). Animal models of cognitive impairment induced by methotrexate. In: Castillo V, Moyano L (eds) Methotrexate: pharmacology, clinical uses and adverse effects. Nova Science Publishers, HauppaugeGoogle Scholar
  128. Lyons L, Elbeltagy M, Bennett G, Wigmore P (2011b) The effect of cyclophosphamide on hippocampal cell proliferation and spatial working memory in the rat. PlosOne 6:e21445Google Scholar
  129. Lyons L, ElBeltagy M, Bennett G, Wigmore P (2012) Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery. PLoS One 7:e30010PubMedGoogle Scholar
  130. Lyons L, Elbeltagy M, Umka J, Markwick R, Startin C, Bennett G, Wigmore P (2011c) Fluoxetine reverses the memory impairment and reduction in proliferation and survival of hippocampal cells caused by mehtotrexate chemotherapy. Psychopharmacology 215:105–115PubMedGoogle Scholar
  131. Maccormick RE (2006) Possible acceleration of aging by adjuvant chemotherapy: a cause of early onset frailty? Med Hypotheses 67:212–215PubMedGoogle Scholar
  132. Macleod JE, DeLeo JA, Hickey WF, Ahles TA, Saykin AJ, Bucci DJ (2007) Cancer chemotherapy impairs contextual but not cue-specific fear memory. Behav Brain Res 181:168–172PubMedGoogle Scholar
  133. Mancuso A, Migliorino M, De Santis S, Saponiero A, De Marinis F (2006) Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy. Ann Oncol 17:146–150PubMedGoogle Scholar
  134. Mar Fan HG, Clemons M, Xu W, Chemerynsky I, Breunis H, Braganza S, Tannock IF (2008) A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 16:577–583PubMedGoogle Scholar
  135. Mar Fan HG, Houede-Tchen N, Yi QL, Chemerynsky I, Downie FP, Sabate K, Tannock IF (2005) Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025–8032Google Scholar
  136. Marcussen AB, Flagstad P, Kristjansen PE, Johansen FF, Englund U (2008) Increase in neurogenesis and behavioural benefit after chronic fluoxetine treatment in Wistar rats. Acta Neurol Scand 117:94–100PubMedGoogle Scholar
  137. Marin-Burgin A, Schinder AF (2012) Requirement of adult-born neurons for hippocampus-dependent learning. Behav Brain Res 227:391–399PubMedGoogle Scholar
  138. Massa E, Madeddu C, Lusso MR, Gramignano G, Mantovani G (2006) Evaluation of the effectiveness of treatment with erythropoietin on anemia, cognitive functioning and functions studied by comprehensive geriatric assessment in elderly cancer patients with anemia related to cancer chemotherapy. Crit Rev Oncol Hematol 57:175–182PubMedGoogle Scholar
  139. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2010) Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 123:819–828PubMedGoogle Scholar
  140. McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ (2012) Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 30:2500–2508PubMedGoogle Scholar
  141. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R (2008) No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology 18:248–257Google Scholar
  142. Merzoug S, Toumi ML, Boukhris N, Baudin B, Tahraoui A (2011) Adriamycin-related anxiety-like behavior, brain oxidative stress and myelotoxicity in male Wistar rats. Pharmacol Biochem Behav 99:639–647PubMedGoogle Scholar
  143. Meunier J, Ieni J, Maurice T (2006) The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor. Br J Pharmacol 149:998–1012PubMedGoogle Scholar
  144. Ming GL, Song H (2011) Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 70:687–702PubMedGoogle Scholar
  145. Minzenberg MJ, Carter CS (2008) Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33:1477–1502PubMedGoogle Scholar
  146. Miskowiak K, O’Sullivan U, Harmer CJ (2007) Erythropoietin enhances hippocampal response during memory retrieval in humans. J Neurosci 27:2788–2792PubMedGoogle Scholar
  147. Mitchell T, Turton P (2011) ‘Chemobrain’: concentration and memory effects in people receiving chemotherapy—a descriptive phenomenological study. Eur J Cancer Care (Engl) 20:539–548Google Scholar
  148. Mohamed Ariff I, Mitra A, Basu A (2012) Epigenetic regulation of self-renewal and fate determination in neural stem cells. J Neurosci Res 90:529–539PubMedGoogle Scholar
  149. Mondie CM, Vandergrift KA, Wilson CL, Gulinello ME, Weber ET (2010) The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice. Behav Brain Res 209:66–72PubMedGoogle Scholar
  150. Monje M, Dietrich J (2012) Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis. Behav Brain Res 227:376–379Google Scholar
  151. Mowla A, Mosavinasab M, Pani A (2007) Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial. J Clin Psychopharmacol 27:67–70PubMedGoogle Scholar
  152. Mustafa S, Walker A, Bennett G, Wigmore PM (2008) 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus. Eur J Neurosci 28:323–330PubMedGoogle Scholar
  153. Myers JS (2010) The possible role of cytokines in chemotherapy-induced cognitive deficits. Adv Exp Med Biol 678:119–123PubMedGoogle Scholar
  154. Myers JS (2012) Chemotherapy-related cognitive impairment: the breast cancer experience. Oncol Nurs Forum 39:E31–E40PubMedGoogle Scholar
  155. O’Leary OF, Wu X, Castren E (2009) Chronic fluoxetine treatment increases expression of synaptic proteins in the hippocampus of the ovariectomized rat: role of BDNF signalling. Psychoneuroendocrinology 34:367–381PubMedGoogle Scholar
  156. O’Shaughnessy JA, Vukelja SJ, Holmes FA, Savin M, Jones M, Royall D, George M, Von Hoff D (2005) Feasibility of quantifying the effects of epoetin alfa therapy on cognitive function in women with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. Clin Breast Cancer 5:439–446PubMedGoogle Scholar
  157. Oster HS, Neumann D, Hoffman M, Mittelman M (2012) Erythropoietin: the swinging pendulum. Leuk Res 36:939–944PubMedGoogle Scholar
  158. Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165–176PubMedGoogle Scholar
  159. Palmer TD, Willhoite AR, Gage FH (2000) Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 425:479–494PubMedGoogle Scholar
  160. Pechnick RN, Zonis S, Wawrowsky K, Cosgayon R, Farrokhi C, Lacayo L, Chesnokova V (2011) Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One 6:e27290PubMedGoogle Scholar
  161. Phillips KM, Jim HS, Small BJ, Laronga C, Andrykowski MA, Jacobsen PB (2011) Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 118:1925–1932PubMedGoogle Scholar
  162. Ponce LL, Navarro JC, Ahmed O, Robertson CS (2012) Erythropoietin neuroprotection with traumatic brain injury. Pathophysiology (Epub ahead of print)Google Scholar
  163. Potrata B, Cavet J, Blair S, Howe T, Molassiotis A (2010) ‘Like a sieve’: an exploratory study on cognitive impairments in patients with multiple myeloma. Eur J Cancer Care (Engl) 19:721–728Google Scholar
  164. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D et al (2004) Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25:94–102PubMedGoogle Scholar
  165. Pyter LM, Cochrane SF, Ouwenga RL, Patel PN, Pineros V, Prendergast BJ (2010) Mammary tumors induce select cognitive impairments. Brain Behav Immun 24:903–907PubMedGoogle Scholar
  166. Pyter LM, Pineros V, Galang JA, McClintock MK, Prendergast BJ (2009) Peripheral tumors induce depressive-like behaviors and cytokine production and alter hypothalamic-pituitary-adrenal axis regulation. Proc Natl Acad Sci USA 106:9069–9074PubMedGoogle Scholar
  167. Quesnel C, Savard J, Ivers H (2009) Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 116:113–123PubMedGoogle Scholar
  168. Randall TD, Weissman IL (1997) Phenotypic and functional changes induced at the clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood 89:3596–3606PubMedGoogle Scholar
  169. Ransome MI, Turnley AM (2007) Systemically delivered erythropoietin transiently enhances adult hippocampal neurogenesis. J Neurochem 102:1953–1965PubMedGoogle Scholar
  170. Rebbaa A, Zheng X, Chu F, Mirkin BL (2006) The role of histone acetylation versus DNA damage in drug-induced senescence and apoptosis. Cell Death Differ 13:1960–1967PubMedGoogle Scholar
  171. Reid-Arndt SA, Hsieh C, Perry MC (2010) Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer. Psychooncology 19:535–544PubMedGoogle Scholar
  172. Repantis D, Schlattmann P, Laisney O, Heuser I (2010) Modafinil and methylphenidate for neuroenhancement in healthy individuals: a systematic review. Pharmacol Res 62:187–206PubMedGoogle Scholar
  173. Riquelme PA, Drapeau E, Doetsch F (2008) Brain micro-ecologies: neural stem cell niches in the adult mammalian brain. Philos Trans R Soc Lond B Biol Sci 363:123–137PubMedGoogle Scholar
  174. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R, Smith B (2005) Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89:243–249PubMedGoogle Scholar
  175. Rzeski W, Pruskil S, Macke A, Felderhoff-Mueser U, Reiher AK, Hoerster F, Jansma C, Jarosz B, Stefovska V, Bittigau P et al (2004) Anticancer agents are potent neurotoxins in vitro and in vivo. Ann Neurol 56:351–360PubMedGoogle Scholar
  176. Schagen SB, Muller MJ, Boogerd W, Mellenbergh GJ, van Dam FS (2006) Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98:1742–1745PubMedGoogle Scholar
  177. Schagen SB, Muller MJ, Boogerd W, Rosenbrand RM, van Rhijn D, Rodenhuis S, van Dam FS (2002) Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. Ann Oncol 13:1387–1397PubMedGoogle Scholar
  178. Schanzer A, Wachs FP, Wilhelm D, Acker T, Cooper-Kuhn C, Beck H, Winkler J, Aigner L, Plate KH, Kuhn HG (2004) Direct stimulation of adult neural stem cells in vitro and neurogenesis in vivo by vascular endothelial growth factor. Brain Pathol 14:237–248PubMedGoogle Scholar
  179. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2012a) Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci 5:122Google Scholar
  180. Scherling C, Collins B, Mackenzie J, Bielajew C, Smith A (2012b) Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol 34:543–560Google Scholar
  181. Scherwath A, Mehnert A, Schleimer B, Schirmer L, Fehlauer F, Kreienberg R, Metzner B, Thiel E, Zander AR, Schulz-Kindermann F et al (2006) Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol 17:415–423PubMedGoogle Scholar
  182. Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS et al (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28:1294–1300PubMedGoogle Scholar
  183. Seigers R, Fardell JE (2011) Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev 35:729–741PubMedGoogle Scholar
  184. Seigers R, Schagen SB, Coppens CM, van der Most PJ, van Dam FS, Koolhaas JM, Buwalda B (2009) Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats. Behav Brain Res 201:279–284PubMedGoogle Scholar
  185. Seigers R, Pourtau L, Schagen SB, van Dam FS, Koolhaas JM, Konsman JP, Buwalda B (2010a) Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor. Brain Res Bull 81:472–476PubMedGoogle Scholar
  186. Seigers R, Timmermans J, van der Horn HJ, de Vries EF, Dierckx RA, Visser L, Schagen SB, van Dam FS, Koolhaas JM, Buwalda B (2010b) Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release. Behav Brain Res 207:265–272PubMedGoogle Scholar
  187. Sharpe MJ, Fardell JE, Vardy J, Johnston IN (2012) The chemotherapy agent oxaliplatin impairs the renewal of fear to an extinguished conditioned stimulus in rats. Behav Brain Res 227:295–299PubMedGoogle Scholar
  188. Shaw EG, Rosdhal R, D’Agostino RB, Jr Lovato J, Naughton MJ, Robbins ME, Rapp SR (2006). Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol 24:1415–1420Google Scholar
  189. Shen Q, Goderie SK, Jin L, Karanth N, Sun Y, Abramova N, Vincent P, Pumiglia K, Temple S (2004) Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science 304:1338–1340PubMedGoogle Scholar
  190. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, Waddell K, Petersen L, Phelps ME, Ganz PA (2007) Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat 103:303–311PubMedGoogle Scholar
  191. Small BJ, Rawson KS, Walsh E, Jim HS, Hughes TF, Iser L, Andrykowski MA, Jacobsen PB (2011) Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117:1369–1376PubMedGoogle Scholar
  192. Steffener J, Stern Y (2012) Exploring the neural basis of cognitive reserve in aging. Biochim Biophys Acta 1822:467–473PubMedGoogle Scholar
  193. Subiros N, Del Barco DG, Coro-Antich RM (2012) Erythropoietin: still on the neuroprotection road. Ther Adv Neurol Disord 5:161–173PubMedGoogle Scholar
  194. Sun J, Ming GL, Song H (2011) Epigenetic regulation of neurogenesis in the adult mammalian brain. Eur J Neurosci 33:1087–1093PubMedGoogle Scholar
  195. Tager FA, McKinley PS, Schnabel FR, El-Tamer M, Cheung YK, Fang Y, Golden CR, Frosch ME, Habif U, Mulligan MM et al (2010) The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat 123:25–34PubMedGoogle Scholar
  196. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, St Clair W, Ratanachaiyavong S, St Clair DK, Butterfield DA (2006) Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 23:127–139Google Scholar
  197. Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D et al (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183PubMedGoogle Scholar
  198. Tsavaris N, Kosmas C, Vadiaka M, Kanelopoulos P, Boulamatsis D (2002) Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br J Cancer 87:21–27PubMedGoogle Scholar
  199. Umka J, Mustafa S, Elbeltagy M, Thorpe A, Latif L, Bennett G, Wigmore PM (2010) Valproic acid reduces spatial working memory and cell proliferation in the hippocampus. Neuroscience 166:15–22PubMedGoogle Scholar
  200. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, Rodenhuis S (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210–218Google Scholar
  201. van Praag H, Shubert T, Zhao C, Gage FH (2005) Exercise enhances learning and hippocampal neurogenesis in aged mice. J Neurosci 25:8680–8685PubMedGoogle Scholar
  202. Vearncombe KJ, Rolfe M, Andrew B, Pachana NA, Wright M, Beadle G (2011) Cognitive effects of chemotherapy-induced menopause in breast cancer. Clin Neuropsychol 25:1295–1313PubMedGoogle Scholar
  203. Vearncombe KJ, Rolfe M, Wright M, Pachana NA, Andrew B, Beadle G (2009) Predictors of cognitive decline after chemotherapy in breast cancer patients. J Int Neuropsychol Soc 15:951–962PubMedGoogle Scholar
  204. Volz TJ (2008) Neuropharmacological mechanisms underlying the neuroprotective effects of methylphenidate. Curr Neuropharmacol 6:379–385PubMedGoogle Scholar
  205. von Bohlen und Halbach O (2011) Immunohistological markers for proliferative events, gliogenesis, and neurogenesis within the adult hippocampus. Cell Tissue Res 345:1–19Google Scholar
  206. Walker EA, Foley JJ, Clark-Vetri R, Raffa RB (2011) Effects of repeated administration of chemotherapeutic agents tamoxifen, methotrexate, and 5-fluorouracil on the acquisition and retention of a learned response in mice. Psychopharmacology (Berl) 217:539–548Google Scholar
  207. Wang Y, Probin V, Zhou D (2006) Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev 2:271–279PubMedGoogle Scholar
  208. Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA (2004) The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer 100:2292–2299PubMedGoogle Scholar
  209. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA (2010) Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348–3356PubMedGoogle Scholar
  210. Wefel JS, Vardy J, Ahles T, Schagen SB (2011) International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703–708PubMedGoogle Scholar
  211. Weis J, Poppelreuter M, Bartsch HH (2009) Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: ‘subjective’ complaints and ‘objective’ neuropsychological test results. Psychooncology 18:775–782PubMedGoogle Scholar
  212. Whitney KA, Lysaker PH, Steiner AR, Hook JN, Estes DD, Hanna NH (2008) Is “chemobrain” a transient state? A prospective pilot study among persons with non-small cell lung cancer. J Support Oncol 6:313–321PubMedGoogle Scholar
  213. Wick A, Wick W, Hirrlinger J, Gerhardt E, Dringen R, Dichgans J, Weller M, Schulz JB (2004) Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity. J Neurochem 91:1067–1074PubMedGoogle Scholar
  214. Wieneke MH, Dienst ER (1995) Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-oncology 4:61–66Google Scholar
  215. Wigmore PM, Mustafa S, El-Beltagy M, Lyons L, Umka J, Bennett G (2010) Effects of 5-FU. Adv Exp Med Biol 678:157–164PubMedGoogle Scholar
  216. Wilson CL, Weber ET (2013) Chemotherapy drug thioTEPA exacerbates stress-induced anhedonia and corticosteroid responses but not impairment of hippocampal cell proliferation in adult mice. Behav Brain Res 236C:180–185Google Scholar
  217. Winocur G, Binns MA, Tannock I (2011) Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model. Neuropharmacology 61:1222–1228PubMedGoogle Scholar
  218. Winocur G, Henkelman M, Wojtowicz JM, Zhang H, Binns MA, Tannock IF (2012) The effects of chemotherapy on cognitive function in a mouse model: a prospective study. Clin Cancer Res 18:3112–3121PubMedGoogle Scholar
  219. Wong-Goodrich SJ, Pfau ML, Flores CT, Fraser JA, Williams CL, Jones LW (2010) Voluntary running prevents progressive memory decline and increases adult hippocampal neurogenesis and growth factor expression after whole-brain irradiation. Cancer Res 70:9329–9338PubMedGoogle Scholar
  220. Wu MD, Hein AM, Moravan MJ, Shaftel SS, Olschowka JA, O’Banion MK (2012) Adult murine hippocampal neurogenesis is inhibited by sustained IL-1beta and not rescued by voluntary running. Brain Behav Immun 26:292–300PubMedGoogle Scholar
  221. Yamada TH, Denburg NL, Beglinger LJ, Schultz SK (2010) Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 22:48–54PubMedGoogle Scholar
  222. Yang M, Kim JS, Kim J, Jang S, Kim SH, Kim JC, Shin T, Wang H, Moon C (2012) Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain Res Bull 89:50–56PubMedGoogle Scholar
  223. Yang M, Kim JS, Kim J, Kim SH, Kim JC, Wang H, Shin T, Moon C (2011) Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro. Biochem Pharmacol 82:72–80PubMedGoogle Scholar
  224. Yang M, Kim JS, Song MS, Kim SH, Kang SS, Bae CS, Kim JC, Wang H, Shin T, Moon C (2010) Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits. Neurobiol Learn Mem 93:487–494PubMedGoogle Scholar
  225. Yoshikawa E, Matsuoka Y, Inagaki M, Nakano T, Akechi T, Kobayakawa M, Fujimori M, Nakaya N, Akizuki N, Imoto S et al (2005) No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 92:81–84PubMedGoogle Scholar
  226. Yoshiyama Y, Kojima A, Ishikawa C, Arai K (2010) Anti-inflammatory action of donepezil ameliorates tau pathology, synaptic loss, and neurodegeneration in a tauopathy mouse model. J Alzheimers Dis 22:295–306PubMedGoogle Scholar
  227. Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S (2004) Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 85:1050–1055PubMedGoogle Scholar
  228. Zhang Y, Gao Y, Zhang G, Huang S, Dong Z, Kong C, Su D, Du J, Zhu S, Liang Q et al (2011) DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells. Int J Cancer 128:551–561PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.School of Biomedical SciencesQueen’s Medical CentreNottinghamUK

Personalised recommendations